| Market Cap | 162.97M | P/E | - | EPS this Y | -27.70% | Ern Qtrly Grth | - |
| Income | -66.81M | Forward P/E | -7.40 | EPS next Y | 66.90% | 50D Avg Chg | -7.00% |
| Sales | 23.69M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -7.00% |
| Dividend | N/A | Price/Book | 2.28 | EPS next 5Y | - | 52W High Chg | -30.00% |
| Recommedations | 1.90 | Quick Ratio | 1.91 | Shares Outstanding | 52.62M | 52W Low Chg | 19.00% |
| Insider Own | 6.71% | ROA | -37.41% | Shares Float | 49.29M | Beta | 1.95 |
| Inst Own | 30.69% | ROE | -132.32% | Shares Shorted/Prior | 3.77M/3.82M | Price | 4.81 |
| Gross Margin | 75.13% | Profit Margin | -282.01% | Avg. Volume | 279,700 | Target Price | 21.60 |
| Oper. Margin | -534.84% | Earnings Date | Nov 5 | Volume | 112,464 | Change | -1.84% |
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
| Cantor Fitzgerald | Overweight | Oct 1, 24 |
| HC Wainwright & Co. | Buy | Sep 30, 24 |
| JMP Securities | Market Outperform | Sep 24, 24 |
| Maxim Group | Buy | Sep 24, 24 |
| Roth MKM | Buy | Sep 24, 24 |
| HC Wainwright & Co. | Buy | Sep 20, 24 |
| Canaccord Genuity | Buy | Sep 18, 24 |
| Cantor Fitzgerald | Overweight | Aug 14, 24 |
| Cantor Fitzgerald | Overweight | Aug 5, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Schafer Joshua | CCO & EVP, Bus. Deve.. CCO & EVP, Bus. Development | Sep 05 | Buy | 5.129 | 500 | 2,564 | 3,500 | 09/06/23 |
| Clifton R. LaDuane | CFO, Secretary & Tre.. CFO, Secretary & Treasurer | Sep 06 | Buy | 4.9591 | 1,000 | 4,959 | 15,309 | 09/06/23 |
| Schafer Joshua | CCO & EVP, Bus. Deve.. CCO & EVP, Bus. Development | May 19 | Buy | 5.4157 | 1,000 | 5,416 | 3,000 | 06/30/23 |
| Watton Corey Michael | Director Director | Jun 09 | Buy | 5.52 | 325 | 1,794 | 725 | 06/13/23 |
| Watton Corey Michael | Director Director | May 30 | Buy | 5.1053 | 400 | 2,042 | 400 | 05/31/23 |
| Clifton R. LaDuane | CFO, Secretary & Tre.. CFO, Secretary & Treasurer | May 18 | Buy | 4.95 | 2,740 | 13,563 | 13,742 | 05/18/23 |
| Schafer Joshua | CCO & EVP, Bus. Deve.. CCO & EVP, Bus. Development | Mar 14 | Buy | 4.6089 | 2,000 | 9,218 | 2,000 | 03/15/23 |
| Plooster Matthew R | Director Director | Mar 09 | Buy | 4.19530 | 11,000 | 46,148 | 18,500 | 03/13/23 |
| Sangiovanni Timothy J. | SVP, Corporate Contr.. SVP, Corporate Controller | Mar 10 | Buy | 4.14 | 1,200 | 4,968 | 4,449 | 03/13/23 |
| Clifton R. LaDuane | CFO, Secretary & Tre.. CFO, Secretary & Treasurer | Mar 10 | Buy | 4.15 | 1,725 | 7,159 | 11,002 | 03/13/23 |
| Tierney David S | Director Director | Mar 09 | Buy | 4.1463 | 5,000 | 20,732 | 10,835 | 03/13/23 |
| Pascoe Richard W | Chief Executive Offi.. Chief Executive Officer | Mar 09 | Buy | 4.19780 | 10,000 | 41,978 | 29,973 | 03/13/23 |
| Clifton R. LaDuane | CFO, Secretary & Tre.. CFO, Secretary & Treasurer | Jan 13 | Buy | 5.7 | 635 | 3,620 | 9,277 | 01/13/23 |
| Pascoe Richard W | Chief Executive Offi.. Chief Executive Officer | Jan 13 | Buy | 5.4399 | 9,500 | 51,679 | 19,973 | 01/13/23 |
| Tierney David S | Director Director | May 25 | Buy | 4.39 | 2,000 | 8,780 | 5,835 | 05/26/22 |
| Mickle Travis C | President & CEO President & CEO | May 25 | Buy | 4.38 | 13,000 | 56,940 | 11,034 | 05/25/22 |
| SEYMOUR TAMARA A | Director Director | May 20 | Buy | 4.87 | 200 | 974 | 200 | 05/24/22 |
| Plooster Matthew R | Director Director | May 18 | Buy | 4.96 | 5,000 | 24,800 | 7,500 | 05/18/22 |
| Pascoe Richard W | Executive Chairman Executive Chairman | May 18 | Buy | 4.92 | 5,000 | 24,600 | 8,285 | 05/18/22 |
| Clifton R. LaDuane | CFO, Secretary & Tre.. CFO, Secretary & Treasurer | May 18 | Buy | 4.9992 | 1,200 | 5,999 | 6,440 | 05/18/22 |